Literature DB >> 11341854

The impact of naloxone/lofexidine combination treatment on the opiate withdrawal syndrome.

J. Bearn1, J. Bennett, T. Martin, M. Gossop, J. Strang.   

Abstract

Clinical studies in opiate-dependent patients suggest that detoxification treatment with opiate antagonists may accelerate the resolution of the opiate withdrawal syndrome, permitting early induction onto naltrexone maintenance treatment. The present open study compared the clinical efficacy of daily naloxone injections in conjunction with lofexidine, with conventional lofexidine monotherapy, in 49 polysubstance-misusing opiate-dependent patients. Overall, the addition of naloxone did not confer substantial benefit over lofexidine monotherapy, although area-under-the-curve analysis showed that withdrawal severity in the naloxone/lofexidine combination group was significantly less than in the lofexidine monotherapy group, who experienced more severe withdrawal symptoms on days 4, 7, 9 and 13 of treatment. There were no significant differences in rates of completion of detoxification. Blood pressure remained within normal limits in both groups. Naltrexone maintenance treatment acceptability was low; only four patients continued with treatment for 5 or more days. The modest benefit of adding naloxone to lofexidine compared to the findings of previous opiate antagonist detoxification treatment studies is discussed in the context of the hypothesis that a critical level of opiate receptor occupancy is required to accelerate resolution of opiate withdrawal; the neurochemical mechanisms which may promote this are discussed.

Entities:  

Year:  2001        PMID: 11341854     DOI: 10.1080/13556210020040226

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  6 in total

Review 1.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

2.  Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents.

Authors:  Hassan Ziaaddini; Mansooreh Nasirian; Nouzar Nakhaee
Journal:  Addict Health       Date:  2012 Summer-Autumn

Review 3.  Pharmacological therapies for management of opium withdrawal.

Authors:  Afarin Rahimi-Movaghar; Jaleh Gholami; Laura Amato; Leila Hoseinie; Reza Yousefi-Nooraie; Masoumeh Amin-Esmaeili
Journal:  Cochrane Database Syst Rev       Date:  2018-06-21

Review 4.  Pharmacologic treatments for opioid dependence: detoxification and maintenance options.

Authors:  Herbert D Kleber
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

5.  A comparison of the efficacy of buprenorphine and clonidine in detoxification of heroin-dependents and the following maintenance treatment.

Authors:  Hassan Ziaaddini; Mansooreh Nasirian; Nouzar Nakhaee
Journal:  Addict Health       Date:  2010 Winter-Spring

Review 6.  A Comprehensive Update of Lofexidine for the Management of Opioid Withdrawal Symptoms.

Authors:  Ivan Urits; Anjana Patel; Robbie Zusman; Celina Guadalupe Virgen; Mohammad Mousa; Amnon A Berger; Hisham Kassem; Jai Won Jung; Jamal Hasoon; Alan D Kaye; Omar Viswanath
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.